What is Neuropeptide Y?
Neuropeptide Y is an endogenous signaling peptide involved in feeding circuitry. The selected mouse study examined NPY-related neurons and feeding behavior rather than a clinical peptide treatment.
Biological role or research focus
Feeding-neuron circuitry.
This is not an NPY administration trial in humans. It does not establish a weight-loss therapy or universal effects across NPY receptor pathways.
Role reference: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Names you may encounter
NPY
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Endogenous neuropeptide
- Research focus
- Feeding-neuron circuitry
- Featured evidence
- Animal neurocircuit study
- Source check
- October 4, 2026
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Quick answers
- Is Neuropeptide Y FDA approved?
- No. No FDA-approved drug contains Neuropeptide Y. Source ↗
- Is Neuropeptide Y safe?
- Not an approved drug. Small short trials in PTSD or depression reported NPY was tolerated, but long-term safety is unknown and NPY strongly constricts blood vessels. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Neuropeptide Y banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| NPY-associated feeding circuits in mice (2025) | Animal neurocircuit study | Mice in genetic and chemogenetic feeding-circuit experiments. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal neurocircuit study · 2025
NPY-associated feeding circuits in mice
What did this publication test, and what did it find?
- Population / model
- Mice in genetic and chemogenetic feeding-circuit experiments.
- Study design
- Manipulation of PNOC/NPY-associated neuronal activity and expression, with feeding and weight-related measurements.
- Main finding
- The report linked NPY-associated expression and neuronal activation to increased feeding and weight gain in the tested models.
- Limits & context
- This is not an NPY administration trial in humans. It does not establish a weight-loss therapy or universal effects across NPY receptor pathways.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
10 registered studies name Neuropeptide Y as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 8 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN) NCT04838678 · University of Texas Southwestern Medical Center | Recruiting | Early phase 1 | 2021-07-18 | 100 |
| Neuropeptide Y Regulates Neurogenic Pulp Inflammation NCT06606236 · Institucion Universitaria Colegios de Colombia | Completed | Not applicable | 2024-02-05 | 40 |
| Moxonidine Effects on Neuropeptide Y NCT05147753 · Aristotle University Of Thessaloniki | Completed | Phase 4 | 2010-01-11 | 90 |
| Sex Differences in Neuropeptide Y Serum, But Not in Fat Intake and Body Mass Index NCT04650308 · Universitas Sumatera Utara | Completed | Not applicable | 2020-04-02 | 62 |
| Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder NCT04071600 · New York Medical College | Status unknown | Phase 1 / Phase 2 | 2019-11-01 | 117 |
| Neuropeptide Y and Sympathovagal Balance NCT03933787 · Eric Grouzmann | Completed | Early phase 1 | 2018-06-05 | 7 |
| Effect of DPP4 Inhibition on Vasoconstriction NCT02639637 · Vanderbilt University | Completed | Phase 4 | 2015-12 | 18 |
| Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers NCT00748956 · Dennis Charney | Completed | Phase 2 | 2010-01 | 10 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 10 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Intermittent Fasting Targets Osteocyte Neuropeptide Y to Relieve Osteoarthritis. ↗
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024 Sep · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Neuropeptide Y. ↗
American journal of physiology. Regulatory, integrative and comparative physiology · 2002 Mar · Journal Article, Review
Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1. ↗
Cell reports · 2023 Feb 28 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Neuropeptide Y: An Anti-Aging Player? ↗
Trends in neurosciences · 2015 Nov · Journal Article, Research Support, Non-U.S. Gov't, Review
Risks & interactions
Not an approved drug. Small short trials in PTSD or depression reported NPY was tolerated, but long-term safety is unknown and NPY strongly constricts blood vessels.
Evidence is limited to small randomized studies in PTSD and depression, plus physiology experiments showing NPY is a potent blood-vessel constrictor. No long-term or repeated-use safety studies were found.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Harms seen in animal or lab studies
- In mice, activating NPY-linked brain circuits increased feeding and weight gain
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Randomized dose-ranging study of NPY in PTSD (2018) ↗ · Randomized trial of NPY in major depressive disorder (2020) ↗ · NPY-mediated vasoconstriction in humans (2025) ↗ · Hypothalamic PNOC/NPY neurons and energy homeostasis (Cell, 2025) ↗
Safety & what remains unknown
Complex neurocircuit responses cannot define the safety of an externally administered preparation.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Evidence boundaries
This is not an NPY administration trial in humans. It does not establish a weight-loss therapy or universal effects across NPY receptor pathways.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This is a neurobiology reference, with appetite-related outcomes retained in their experimental setting.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
Genetic and chemogenetic experiments probed the activity of a particular neuronal population. Circuit activation is different from administering an NPY product.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Questions worth asking
- Was the study testing NPY as a human weight-loss treatment?
- What material, population, and route were actually studied?
- This is not an NPY administration trial in humans. It does not establish a weight-loss therapy or universal effects across NPY receptor pathways.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was the study testing NPY as a human weight-loss treatment?
No. It examined mouse neuronal circuitry and reported feeding-promoting responses in its models.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis. · 2025 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
